 | Related Articles |
The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma.
Expert Opin Drug Discov. 2015 Jul;10(7):791-808
Authors: Smolewski P, Robak T
Abstract
INTRODUCTION: Monoclonal antibodies (MoAbs) were developed in the 1980s in order to treat malignancies. An important target for MoAbs was the CD20 B-cell lineage antigen. Rituximab (RTX) is a chimeric mouse anti-human MoAb that targets the CD20 antigen on the surface of malignant and normal B lymphocytes, and has rapidly become the widest used immunotherapeutic drug. RTX has had a significant impact on how B-cell non-Hodgkin's lymphomas (NHLs) and chronic lymphocytic leukemia is now treated.
AREAS COVERED: In this review, the authors demonstrate the mechanisms of action of RTX, and the preclinical data that have led to clinical trials and its final approval for the treatment of B-cell NHLs.
EXPERT OPINION: The discovery of RTX opened a new era for treatment of B-cell malignancies and became the starting point for the development of new, more active classes of anti-CD20 agents. Furthermore, it has contributed to the construction of a number of MoAbs specific for other antigens that target different types of neoplastic cells.
PMID: 26083358 [PubMed - indexed for MEDLINE]
from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/1d3AIv6
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου